Pfizer’s Maternal RSV Vaccine Quest May Hinge On FDA Advisors’ Views of Preterm Birth Data

 
• By Sarah Karlin-Smith

A numerical – but not statistically significant – imbalance in preterm births was seen in two Pfizer studies of its RSV vaccine when given to pregnant people with the aim of protecting newborns.

mom and infant
FDA’s advisors will vote 18 May on Pfizer’s maternal RSV vaccine program to protect infants • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers